A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

NCT04225923 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus Disease

Interventions

DRUG: NPC-21 Low dose
DRUG: NPC-21 High dose
DRUG: NPC-21 Placebo

Sponsor

Nobelpharma